Skip to main content
OpenTrials
Completed

NCT Number: NCT06899074

Omega-3 Supplementation for Pediatric Migraine

The purpose of the study is to assess the biochemical and clinical effects of omega-3 polyunsaturated fatty acid (PUFA) supplementation in youth suffering from migraine, including its effects on migraine disability, psychological distress, and overall quality of life. This study duration 12 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Age range

10 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States

About this study

Omega-3 polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), hold potential therapeutic benefit for pediatric migraine due to their potent anti-inflammatory, anti-nociceptive, and neuromodulatory properties, which impact the pathophysiology of migraine. Dietary alteration and supplementation of omega-3 PUFAs have been shown to decrease the frequency, duration, and severity of headaches in adults with migraine, yet no rigorous clinical studies on omega-3 polyunsaturated fatty acid (PUFA) supplementation have been conducted in children and/or adolescents suffering from migraine. This study will establish feasibility of the intervention of omega-3 PUFA supplementation for pediatric migraine (i.e., provide proof-of-concept that the intervention raises omega-3 index levels compared to placebo).

The investigators will enroll children and adolescents (ages 10-17 years) with a diagnosis of migraine and randomize participants 1:1 to receive an omega-3 PUFA dietary supplement intervention or placebo daily for 12 weeks, with assessments conducted at baseline and at 12 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females between the ages of 10 and 17 years
  • Parent consent and subject assent
  • Diagnosis of migraine based on the third edition of the International Classification of Headache Disorders (ICHD-3) criteria

Exclusion criteria

  • Known allergy to fish or seafood
  • Current use of an omega-3 dietary supplement
  • Significant neurological or psychiatric disorders or developmental delays
  • Non-English speaking
  • Allergy to coconut
  • Pregnancy

Treatment and study plan

Omega 3 Polyunsaturated Fats

Dietary Supplement

Omega-3 PUFA dietary supplement daily for 12 weeks. The intervention is 1 teaspoon of liquid omega-3 containing oil profile 40% EPA / 60% DHA.

Matching Placebo

Other

The placebo is a matched 1 teaspoon liquid of coconut oil, consisting mainly of saturated fatty acids and lacking omega-3 fatty acids.

Other names: Coconut oil

Primary outcomes

  1. Mean Change in Omega-3 Index Levels in Blood

    Time frame: Baseline and 12 weeks

    The Omega-3 Index is defined as the combined percentage of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in red blood cell membranes, expressed as a percentage of total fatty acids. Possible range: 0-100%. Higher values indicate greater incorporation of omega-3-fatty acids (favorable outcome). This outcome compares the change in omega-3 index levels via finger prick blood test.

Secondary outcomes

  1. Mean Self-reported Pain Intensity Levels

    Time frame: Baseline and 12 weeks

    The associations between omega-3 (O3) index levels and pain intensity will be assessed based on validated self-report measures using the Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Pain Intensity Measure (PPIM). The PROMIS Pain Intensity instruments assess how much the child hurts. The PROMIS Pediatric Pain Intensity Measure is a 3-item, self-report measure for children and adolescents ages 8 to 18 with chronic pain, using a 5-point Likert scale including three items rating pain from "Had no pain" = 1 to "Very severe" = 5. Total raw scores for the short form are summed for the values of the response to each question. Raw score range: 3-15. Raw scores are then converted to t-scores using a standardized scale where 50 represents the average of the general US population, and each 10-point difference represents one standard deviation. T-score range: 26.8-74.1. Higher scores indicate worse or more intense pain.

  2. Mean Self-reported Pain Interference Levels

    Time frame: Baseline and 12 weeks

    The associations between omega-3 index levels and pain interference will be assessed based on validated self-report measures using the Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Pain Interference Scale (PPIS). The PROMIS Pediatric Pain Interference Scale is an 8-item self-report questionnaire completed by children that assesses how pain impacts a child's daily activities of living and the enjoyment of those activities using a 5-point likert scale. This survey is measured on a scale of 1-5, from 1 being never to 5 being almost always. A lower score will indicate less pain interference in the pediatric patient. Raw scores are then converted to t-scores using a standardized scale where 50 represents the average of the general US population, and each 10-point difference represents one standard deviation. T-score range: 43.8-83.5.

  3. Migraine Disability as Determined by the PedMIDAS Grade

    Time frame: Baseline and 12 weeks

    The validated Pediatric Migraine Disability Assessment tool (PedMIDAS) was used to measure migraine disability by self-report. PedMIDAS was developed to assess migraine disability in pediatric and adolescent patients ages 4-18. It is intended to be self-administered by the patient and their parent. The PedMIDAS is scored by summing the answers across 6 questions. The raw score ranges from 0 (minimum) to 240 (maximum). Higher scores reflect greater headache-related disability, with clinical cut-off scores graded 0-10 indicating "little to none", 11-30 indicating "mild", 31-50 indicating "moderate", or greater than 50 indicating "severe" migraine disability. The number of participants meeting each category was recorded.

  4. Psychological Distress as Determined by the RCADS

    Time frame: Baseline and 12 weeks

    The validated Revised Children's Anxiety and Depression Scale (RCADS)-short version will be used to measure psychological distress by self-report. The RCADS is a 25-item questionnaire designed to assess symptoms of anxiety and depression in children and adolescents aged 8 to 18 years using a 4-point Likert scale. Each item is assigned a numerical value from 0-3, where 0 = Never, 1 = Sometimes, 2 = Often, and 3 = Always, with a raw score range of 0 to 75. Raw scores are converted to standardized T-scores based on their age (grade level) and gender. T-score range: 24-163. RCADS T-scores a reported with a standardized mean of 50 and a standard deviation of 10. A higher T-score indicates a higher level of anxiety and/or depression in the pediatric patient. These standardized scores indicate the severity of their symptoms compared to peers in the general population. T-scores < 65 indicate normal or low severity; T-scores of 65-69 are borderline; T-scores >/= 70 are clinical severity.

Sponsors and collaborators

Lead sponsor

University of North Carolina, Chapel Hill

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Nutrition Obesity Research Center

Registry information

Official study title

Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids in Pediatric Migraine Patients

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 27, 2025
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.